ArticleDrug design, development and therapy2026
Structure-Based Virtual Screening of New Skp1 Inhibitor Chemotypes Targeting F-Box Binding Interface.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skp1 is a potential pharmacological target for cancer treatment. However, the few Skp1 inhibitors reported to date have exhibited limited structural diversity and target specificity. This highlights the need for new chemical scaffolds that could potentially be developed into potent and specific Skp1 inhibitors. Methods: We performed a large-scale, hierarchical, structure-based virtual screening (SBVS) integrated with molecular dynamics (MD) simulations against a hydrophobic and shallow P1 hotspot region within the F-box binding interface of Skp1, using a commercial compound library (~280,000 compounds). The top-ranked hits were then experimentally validated using in vitro biophysical and biochemical assays, followed by evaluation of cell viability. Results: The SBVS campaign yielded 28 potential hits. Using a thermal stability shift assay (TSA), we confirmed that several compounds directly bind to both full-length Skp1 and its truncated variant containing only the P1 hotspot (Skp1 Conclusion: Compounds #04, #12, and #24 represent interesting scaffolds and may serve as valuable starting points for future structure-activity relationship (SAR) studies aimed at developing a new class of selective Skp1 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.